Bulletin
Investor Alert

Need to Know Archives | Email alerts

Sept. 9, 2020, 8:52 a.m. EDT

Why an approved coronavirus vaccine may not end the pandemic quickly

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Tesla Inc. (TSLA)
  • X
    DocuSign Inc. (DOCU)
  • X
    KLA Corp. (KLAC)

or Cancel Already have a watchlist? Log In

By Steve Goldstein

Tesla Chief Executive Elon Musk did warn you.

In May, when the electric vehicle’s stock was less than half its current value (adjusted for the split), Musk famously tweeted that his company was overvalued. Investors finally shared that view on Tuesday when the stock dropped 21%, its worst-ever decline, after S&P Dow Jones Indices didn’t allow Tesla /zigman2/quotes/203558040/composite TSLA +0.13% into the S&P 500.

Since Sept. 2, the worst Nasdaq-100 performers have been Tesla, electronic-signature provider DocuSign /zigman2/quotes/205992027/composite DOCU -0.54% , semiconductor manufacturing company KLA /zigman2/quotes/209248041/composite KLAC -1.64% , Zoom Video Communications /zigman2/quotes/211319643/composite ZM -0.73% , and computer graphics chipmaker Nvidia /zigman2/quotes/200467500/composite NVDA -1.39% — all except KLA have at least doubled in price this year.

While the timing perhaps came out of the blue, the actual declines can be explained away as a correction to irrational exuberance, for the technology sector in particular.

Also read: Here’s the silver lining — stocks have done well after similar Nasdaq corrections

But one reason for the market’s swagger, at least until September, was the work from multiple companies on a coronavirus vaccine. Evercore ISI hosted a call on this subject, and the takeaway was sobering.

Speaking before the news that AstraZeneca halted its COVID-19 trial because of an illness, analyst Josh Schimmer pointed out that in most vaccines, pharmaceutical companies settle for lower rates of immunity in exchange for better tolerability. Now, he said, companies are pushing the protective profile to go for maximum effect, knowing it may come with more side effects. He put greater than 50/50 odds that the first vaccines will work well — which he defined as either 90% reduction in event rates, or a strong benefit for severe cases.

AstraZeneca /zigman2/quotes/203048482/delayed UK:AZN -0.27% , along with the vaccines created by the Pfizer /zigman2/quotes/202877789/composite PFE +2.58% /BioNTech /zigman2/quotes/214419716/composite BNTX +7.69% collaboration and Moderna /zigman2/quotes/205619834/composite MRNA +6.84% , were seen as the most likely to complete the late-stage trial by October. The Novavax /zigman2/quotes/202614340/composite NVAX +12.50% vaccine, which many investors see as their favorite according to Schimmer, is expected to complete Phase 3 in December.

But the next most likely scenario is they work but not great, like the flu vaccine, in which case, the impact on alleviating the pandemic would be limited. “I don’t know if a 60% efficacy COVID vaccine gets us out of this mess quickly,” he said. ( The minimum effectiveness is 50% ). In that scenario, the hope would be that the second wave of vaccines work better, to “switch vaccine horses midstream if better ones come along.”

There is a lower chance the vaccines don’t work, or make infections worse, or have problematic side effects, he added.

More positively, analyst Vijay Kumar said newly approved rapid, point-of-care antigen tests will be helpful in reopening the economy and alleviate the testing constraints. He said by the first half of next year, anyone who wants a test can go get tested.

The buzz

AstraZeneca /zigman2/quotes/200304487/composite AZN -0.18% said it “ voluntarily paused vaccination to allow review of safety data by an independent committee ,” and described the pause as “routine.” the New York Times reported a volunteer in the U.K. trial had received a diagnosis of transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.

LVMH Moet Hennessy /zigman2/quotes/201350549/delayed FR:MC +2.16% said it will not be able to complete the previously announced $16.2 billion takeover of Tiffany . sending the stock of the U.S. luxury-goods retailer sharply lower in premarket and prompting a lawsuit to enforce the acquisition.

Slack /zigman2/quotes/212180539/composite WORK +0.48% may see pressure after the maker of office-communications software topped analyst expectations on its earnings and outlook , but not by as much as Zoom Video Communications.

Athletic apparel maker Lululemon Athletica /zigman2/quotes/204011506/composite LULU -0.53% reported stronger-than-forecast earnings and revenue.

/zigman2/quotes/203558040/composite
US : U.S.: Nasdaq
$ 739.78
+0.93 +0.13%
Volume: 27.98M
April 16, 2021 4:00p
P/E Ratio
1,177
Dividend Yield
N/A
Market Cap
$709.19 billion
Rev. per Employee
$445,694
loading...
/zigman2/quotes/205992027/composite
US : U.S.: Nasdaq
$ 231.93
-1.27 -0.54%
Volume: 1.89M
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$45.03 billion
Rev. per Employee
$258,090
loading...
/zigman2/quotes/209248041/composite
US : U.S.: Nasdaq
$ 333.00
-5.54 -1.64%
Volume: 958,199
April 16, 2021 4:00p
P/E Ratio
38.01
Dividend Yield
1.08%
Market Cap
$52.16 billion
Rev. per Employee
$547,390
loading...
/zigman2/quotes/211319643/composite
US : U.S.: Nasdaq
$ 329.95
-2.43 -0.73%
Volume: 2.48M
April 16, 2021 4:00p
P/E Ratio
146.91
Dividend Yield
N/A
Market Cap
$97.62 billion
Rev. per Employee
$599,586
loading...
/zigman2/quotes/200467500/composite
US : U.S.: Nasdaq
$ 636.50
-8.99 -1.39%
Volume: 8.38M
April 16, 2021 4:00p
P/E Ratio
92.28
Dividend Yield
0.10%
Market Cap
$401.74 billion
Rev. per Employee
$878,788
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
7,380.00 p
-20.00 -0.27%
Volume: 2.55M
April 16, 2021 4:35p
P/E Ratio
38.95
Dividend Yield
2.80%
Market Cap
£97.14 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 38.57
+0.97 +2.58%
Volume: 52.83M
April 16, 2021 4:02p
P/E Ratio
22.56
Dividend Yield
4.04%
Market Cap
$209.74 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 151.54
+10.82 +7.69%
Volume: 4.62M
April 16, 2021 4:00p
P/E Ratio
1,446
Dividend Yield
N/A
Market Cap
$33.99 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 170.81
+10.94 +6.84%
Volume: 19.04M
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$63.98 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 227.35
+25.26 +12.50%
Volume: 4.51M
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$14.93 billion
Rev. per Employee
$601,262
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 50.74
-0.09 -0.18%
Volume: 22.17M
April 16, 2021 4:00p
P/E Ratio
41.40
Dividend Yield
2.70%
Market Cap
$133.99 billion
Rev. per Employee
$365,423
loading...
/zigman2/quotes/201350549/delayed
FR : France: Euronext Paris
630.00
+13.30 +2.16%
Volume: 587,186
April 16, 2021 5:36p
P/E Ratio
67.56
Dividend Yield
0.95%
Market Cap
€310.75 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/212180539/composite
US : U.S.: NYSE
$ 42.23
+0.20 +0.48%
Volume: 6.29M
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$24.45 billion
Rev. per Employee
$354,660
loading...
/zigman2/quotes/204011506/composite
US : U.S.: Nasdaq
$ 324.10
-1.73 -0.53%
Volume: 923,436
April 16, 2021 4:00p
P/E Ratio
72.05
Dividend Yield
N/A
Market Cap
$42.48 billion
Rev. per Employee
$176,075
loading...
1 2
This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.